An analysis of firm-level innovation strategies in the US biotechnology industry

Abstract This study examines factors that may affect innovation strategies and performance of firms in the biotechnology industry. Specifically, differences between factors common to firms with high R&D intensity and those to firms with low R&D intensity are investigated. Biotechnology firms with relatively higher levels of R&D intensity attribute their innovation performance to research-based innovation factors and strategies such as strengthening their own research capabilities, entering into research collaborations with universities, industry leaders and other biotech firms, and licensing their technology. These strategies can be summarized as alignment within the industry. Firms with relatively lower R&D intensity have a hybrid focus—they invest in R&D but may also have products on the market. These firms attribute their innovation performance more so to production-based innovation factors and strategies such as gaining market access and maintaining connections with customers. Their strategy focuses on competitiveness, marketing, and distribution channels, while not ignoring the importance of a strong research base and the need to advance technologically. In a sense, strategies employed to achieve successful innovation reflect the stage of innovation in which a firm is operating for a particular product or process.

[1]  David J. Teece,et al.  Joint Ventures and Collaboration in the Biotechnology Industry , 1988 .

[2]  S. Bagchi‐Sen.  Firm-specific characteristics of R&D collaborators and non-collaborators in US biotechnology clusters and elsewhere , 2004 .

[3]  David B. Audretsch,et al.  The Role of Small Firms in U.S. Biotechnology Clusters , 2001 .

[4]  Harry Boer,et al.  Knowledge and continuous innovation: The CIMA methodology , 2001 .

[5]  Linda A. Hall,et al.  A study of R&D, innovation, and business performance in the Canadian biotechnology industry , 2002 .

[6]  A. Arora,et al.  Evaluating technological information and utilizing it: Scientific knowledge, technological capability, and external linkages in biotechnology , 1994 .

[7]  Alok K. Chakrabarti,et al.  An empirical analysis of innovation strategies of biotechnology firms in the U.S. , 1991 .

[8]  P. Swann,et al.  Do firms in clusters innovate more , 1998 .

[9]  Mark D. Dibner,et al.  Patterns of Strategic Choice in Emerging Firms: Positioning for Innovation in Biotechnology , 1990 .

[10]  David L. Deeds,et al.  International alliances as sources of capital: Evidence from the biotechnology industry , 2000 .

[11]  David L. Deeds,et al.  Strategic alliances and the rate of new product development: An empirical study of entrepreneurial biotechnology firms , 1996 .

[12]  F. Rothaermel.  Complementary Assets, Strategic Alliances, and the Incumbent's Advantage: An Empirical Study of Industry and Firm Effects in the Biopharmaceutical Industry , 2001 .

[13]  Maryann P. Feldman,et al.  The Geographic Sources of Innovation: Technological Infrastructure and Product Innovation in the United States , 1994 .

[14]  Noel P. Greis,et al.  External partnering as a response to innovation barriers and global competition in biotechnology , 1995 .

[15]  P. Oinas,et al.  The Evolution of Technologies in Time and Space: From National and Regional to Spatial Innovation Systems , 2002 .

[16]  Alfonso Gambardella,et al.  ‘Biological’ revolution and strategies for innovation in pharmaceutical companies , 1993 .

[17]  David B. Audretsch,et al.  The role of small firms in US biotechnology clusters , 2003 .

[18]  C. Freeman.  Networks of innovators: A synthesis of research issues , 1991 .

[19]  John Hagedoorn,et al.  Strategic technology partnering during the 1980s: Trends, networks and corporate patterns in non-core technologies , 1995 .

[20]  Mile Terziovski,et al.  Management practices and strategies to accelerate the innovation cycle in the biotechnology industry , 2006 .

[21]  S. Negassi,et al.  Is technology integration the solution to biotechnology's low research and development productivity? , 2006 .

[22]  J. Hagedoorn.  Inter-firm R&D partnerships: an overview of major trends and patterns since 1960 , 2002 .

[23]  L. Defrancesco,et al.  Public biotechnology 2002—the numbers , 2003, Nature Biotechnology.

[24]  Paul Zarowin,et al.  The boundaries of financial reporting and how to extend them , 1999 .

[25]  D. Mowery,et al.  Technology and the pursuit of economic growth , 1991 .

[26]  Satish Nambisan,et al.  Complementary Product Integration by High-Technology New Ventures: The Role of Initial Technology Strategy , 2002, Manag. Sci..

[27]  B. Kogut,et al.  Interfirm cooperation and startup innovation in the biotechnology industry , 1994 .

[28]  V. Sabourin,et al.  Strategic formation of competitive high technology clusters , 1997 .